Last reviewed · How we verify
antihypertensive therapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
antihypertensive therapy (antihypertensive therapy) — Center of Personalized Medicine, Pirogova.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| antihypertensive therapy TARGET | antihypertensive therapy | Center of Personalized Medicine, Pirogova | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- antihypertensive therapy CI watch — RSS
- antihypertensive therapy CI watch — Atom
- antihypertensive therapy CI watch — JSON
- antihypertensive therapy alone — RSS
Cite this brief
Drug Landscape (2026). antihypertensive therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/antihypertensive-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing